Ingenol mebutate 0.015% gel is safe for short-term treatment of actinic keratoses on the face in solid organ transplant recipients.
Abstract Immunosuppressed solid organ transplant recipients (SOTR) have a high burden of AK, but have been excluded from clinical trials of ingenol mebutate 0.015% gel. This leaves dermatologists and transplant teams to extrapolate safety data from immunocompetent patients or from two case reports of use in SOTR. This single-arm, open-label investigator-initiated study investigated the safety and tolerability of topical ingenol mebutate 0.015% gel in SOTR. PMID: 32221965 [PubMed - as supplied by publisher] (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - March 27, 2020 Category: Dermatology Authors: Crow LD, Yuan JT, Aroyan CS, Twigg AR, Singer JP, Roll GR, Lazar AA, Arron ST Tags: Br J Dermatol Source Type: research

Modalities of use of oral propranolol in proliferative infantile hemangiomas: an international survey among practitioners.
Abstract Infantile hemangiomas (IHs) are common benign vascular tumours in infants (estimated prevalence 5% to 10%).1 Oral propranolol is currently the first-line treatment for complicated proliferative IHs.2 It is approved by the US Food and Drug Administration and the European Medicines Agency for treating complicated IHs, but questions remain regarding the optimal modalities of use.3 We conducted an international survey to assess practices in prescribing oral propranolol for IHs among practitioners dealing with IHs worldwide. PMID: 32221977 [PubMed - as supplied by publisher] (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - March 27, 2020 Category: Dermatology Authors: Robert J, Tavernier E, Boccara O, Mashiah J, Mazereeuw-Hautier J, Maruani A Tags: Br J Dermatol Source Type: research

Frontal Fibrosing Alopecia shows robust Th1 and JAK3 skewing.
Abstract BACKGROUND: Frontal Fibrosing Alopecia (FFA) is a scarring alopecia with unclear pathogenesis and a progressive course. The disease has a major impact on patients' quality of life, lacking effective treatments to halt disease progression. METHODS: We profiled lesional and non-lesional scalp biopsies collected in 2017 from FFA patients (n=12) in comparison to scalp biopsies from alopecia areata (AA) (n=8) and control (n=8) individuals to evaluate gene and protein expression including the primary outcome (CXCL9). We determined significant differences between biomarkers by a two-sided Student's t-test a...
Source: The British Journal of Dermatology - March 25, 2020 Category: Dermatology Authors: Del Duca E, Ruano Ruiz J, Pavel AB, Dutt Sanyal R, Song T, Gay-Mimbrera J, Zhang N, Estrada YD, Peng X, Renert-Yuval Y, Phelps RG, Paus R, Krueger JG, Guttman-Yassky E Tags: Br J Dermatol Source Type: research

Lichen planopilaris and frontal fibrosing alopecia: branches from the same tree bear different fruits.
PMID: 32196647 [PubMed - as supplied by publisher] (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - March 20, 2020 Category: Dermatology Authors: Kinoshita-Ise M Tags: Br J Dermatol Source Type: research

No association between whole-body UVA1 phototherapy and skin cancers in humans: a cancer registry linkage study.
Abstract Ultraviolet A1 (UVA1) phototherapy was first developed in the 1980s.1 Its use started in the UK in Dundee in 1996.2 It is not available in most centres despite being useful for some of the sclerosing/fibrosing conditions and granulomatous conditions. Where available, for some individuals, it can be very helpful for other indications such as atopic eczema.3 A concern is that sufficient exposures might increase the risk of skin cancer.4 Itt has been shown to produce cyclobutane-pyrimidine dimers in humans,5 and so has the potential to be carcinogenic. PMID: 32198750 [PubMed - as supplied by publisher] ...
Source: The British Journal of Dermatology - March 20, 2020 Category: Dermatology Authors: Bedair K, Elhadad A, Hamad S, Ferguson J, Donnan P, Dawe RS Tags: Br J Dermatol Source Type: research

The efficacy of eribulin mesylate for patients with cutaneous angiosarcoma previously treated with taxane: a multi-center, prospective, observational study.
Abstract BACKGROUND: Taxanes are the current first-line treatment for advanced cutaneous angiosarcoma (CAS) for patients who considered difficult to treat with doxorubicin due to high age or comorbidity. However, no effective second-line therapy for such patients has been established. METHODS: We designed a single-arm, prospective observational study of eribulin mesylate (ERB) administered at a dose of 1.4mg/m2 on days 1 and 8 in a 21-day cycle. Advanced CAS patients previously treated with taxane scheduled for ERB use were enrolled. The primary endpoint was overall survival (OS) and the secondary endpoi...
Source: The British Journal of Dermatology - March 20, 2020 Category: Dermatology Authors: Fujisawa Y, Fujimura T, Matsushita S, Yamamoto Y, Uchi H, Otsuka A, Funakoshi T, Miyagi T, Hata H, Gosho M, Kambayashi Y, Aoki M, Yanagi T, Ohira A, Nakamura Y, Maeda T, Yoshino K Tags: Br J Dermatol Source Type: research

British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020 - a rapid update.
; Clinical Standards Unit Abstract The overall aim of the guideline is to provide up-to-date, evidence-based recommendations on the use of biologic therapies targeting TNF (adalimumab, etanercept, certolizumab pegol, infliximab), IL12/23p40 (ustekinumab), IL17A (ixekizumab, secukinumab), IL17RA (brodalumab) and IL23p19 (guselkumab, risankizumab, tildrakizumab) in adults, children and young people for the treatment of psoriasis; consideration is given to the specific needs of people with psoriasis and psoriatic arthritis. PMID: 32189327 [PubMed - as supplied by publisher] (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - March 18, 2020 Category: Dermatology Authors: Smith CH, Yiu ZZ, Bale T, Burden AD, Coates LC, Edwards W, MacMahon E, Mahil S, McGuire A, Murphy R, Nelson-Piercy C, Owen CM, Parslew R, Uthman OA, Woolf RT, Manounah L, Ezejimofor MC, Exton LS, Mohd Mustapa MF, British Association of Dermatologists’ C Tags: Br J Dermatol Source Type: research

Expanding treatment options for rosacea.
PMID: 32189331 [PubMed - as supplied by publisher] (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - March 18, 2020 Category: Dermatology Authors: Hampton PJ Tags: Br J Dermatol Source Type: research

Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in pediatric patients ( ≥6 to < 12 years of age): efficacy, safety, pharmacokinetic, and biomarker results from the open-label CADMUS Jr study.
Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in pediatric patients (≥6 to
Source: The British Journal of Dermatology - March 16, 2020 Category: Dermatology Authors: Philipp S, Menter A, Nikkels AF, Barber K, Landells I, Eichenfield LF, Song M, Randazzo B, Li S, Hsu MC, Zhu Y, DePrimo S, Paller AS Tags: Br J Dermatol Source Type: research

Antiseptic Use in Mohs Micrographic Surgery: British Society for Dermatological Surgery and Australasian College of Dermatologists Survey.
Abstract In Mohs Micrographic Surgery (MMS), cleansing the surgical site to reduce the risk of wound infection is performed with a range of antiseptic agents. A recent Cochrane review1 in 2015 suggested that 0.5% chlorhexidine in methylated spirits is superior in reducing surgical site infections, although more evidence is needed. These commonly used chlorhexidine-based antiseptics have been examined in a recent review by Steinsapir & Woodward2 , and shown to be a toxic risk to the cornea and middle ear. Many of these cases2 of chlorhexidine toxicity occurred under general anaesthetic where the incident can go...
Source: The British Journal of Dermatology - March 13, 2020 Category: Dermatology Authors: Swan BC, Patalay R, Mallipeddi R Tags: Br J Dermatol Source Type: research

Assessing uptake of the Harmonising Outcome Measures for Eczema (HOME) Core Outcome Set and Recommended Instruments.
Abstract The Harmonising Outcome Measures for Eczema (HOME) initiative has recommended a Core Outcome Set (COS) for atopic eczema clinical trials1 . Adherence to this COS in future clinical trials of atopic eczema treatments will ensure outcomes are measured and reported consistently, thus allowing direct comparison and minimising bias2 . The COS consists of domains (what should be measured) and instruments (how to measure it). In 2011 four core domains were agreed i) clinician-reported signs, ii) patient-reported symptoms, iii) dermatology-specific quality of life (QoL) and iv) long-term control. EASI (Eczema Are...
Source: The British Journal of Dermatology - March 13, 2020 Category: Dermatology Authors: Vincent R, Chalmers JR, McWilliams C, Thomas KS, Dodd S, Rogers N, Ridd MJ, Schmitt J, Kirkham JJ Tags: Br J Dermatol Source Type: research

Development of the Scalp Hair Assessment Patient-Reported Outcome ™ (PRO) Measure for Alopecia Areata.
CONCLUSIONS: The Scalp Hair Assessment PRO™ is a content-valid, clinically meaningful assessment of distinct gradations of scalp hair loss for evaluating AA treatment for patients with ≥50% hair loss at baseline. PMID: 32163589 [PubMed - as supplied by publisher] (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - March 12, 2020 Category: Dermatology Authors: Wyrwich KW, Kitchen H, Knight S, Aldhouse NVJ, Macey J, Nunes FP, Dutronc Y, Mesinkovska N, Ko JM, King BA Tags: Br J Dermatol Source Type: research

Therapeutic options for erosive pustular dermatosis of the scalp: a systematic review.
CONCLUSIONS: The limited available evidence supports use of topical corticosteroids, with or without oral zinc, followed by maintenance therapy with topical calcineurin inhibitors as effective in managing this condition. Topical photodynamic therapy is also potentially beneficial in the management of EPDS. Prospective, comparative, randomised controlled trials are required in order to provide further evidence to guide treatment. PMID: 32163590 [PubMed - as supplied by publisher] (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - March 12, 2020 Category: Dermatology Authors: Junejo MH, Kentley J, Rajpopat M, Tan XL, Mustapa MFM, Harwood CA Tags: Br J Dermatol Source Type: research

Is psoriasis associated with dementia or cognitive impairment? A Critically Appraised Topic.
DISCUSSION AND RECOMMENDATION FOR CLINICAL CASE: Most studies found a positive association between psoriasis with either mild cognitive impairment or dementia. Brief cognitive assessments has been suggested to screen older psoriasis patients who present with subjective cognitive complaints. PMID: 32162307 [PubMed - as supplied by publisher] (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - March 11, 2020 Category: Dermatology Authors: Yen H, Yen H, Chi CC Tags: Br J Dermatol Source Type: research

Identification and Evaluation of Outcome Measurement Instruments in Pyoderma Gangrenosum: A Systematic Review.
CONCLUSIONS: Seventeen invalidated outcome measurement instruments have been used in clinical trials for PG. We conclude that PG validation studies are required for existing instruments and new instruments need to be developed to inform the consensus process for the development of a core outcome set for PG. PMID: 32159849 [PubMed - as supplied by publisher] (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - March 11, 2020 Category: Dermatology Authors: Lu JD, Hobbs MM, Huang WW, Ortega-Loayza AG, Alavi A Tags: Br J Dermatol Source Type: research

Older adults on systemic treatment for psoriasis and risk of infection: a propensity score matched population-based study.
This study sought to compare the 6-month risk of serious bacterial and opportunistic infections among older adults with psoriasis (PsO) who initiated biologic agents vs. systemic non-biologic agents vs. phototherapy. PMID: 32159850 [PubMed - as supplied by publisher] (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - March 11, 2020 Category: Dermatology Authors: Schneeweiss MC, Perez-Chada L, Gottlieb AB, Merola J Tags: Br J Dermatol Source Type: research

Understanding how young people perceive acne and acne treatments.
PMID: 32147809 [PubMed - as supplied by publisher] (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - March 9, 2020 Category: Dermatology Authors: Prior J Tags: Br J Dermatol Source Type: research

Sentinel lymph node positivity and overall survival in immunosuppressed patients with Merkel cell carcinoma: A national cohort study.
Abstract Merkel cell carcinoma (MCC), a neuroendocrine cutaneous malignancy, may be especially aggressive in immunocompromised patients.1,2 Factors associated with sentinel lymph node (SLN) involvement and overall survival (OS) have been described for the general population with clinically-localized MCC, but prognostic factors in immunosuppressed patients have not been well characterized.3,4 The study objectives were to identify characteristics associated with SLN status and OS in this patient population. PMID: 32147810 [PubMed - as supplied by publisher] (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - March 9, 2020 Category: Dermatology Authors: Song Y, Zheng C, Shannon AB, Fraker DL, Miura JT, Karakousis GC Tags: Br J Dermatol Source Type: research

Bowen disease of the nail apparatus with HPV16 positivity and resolution with human papillomavirus vaccination.
PMID: 32147811 [PubMed - as supplied by publisher] (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - March 9, 2020 Category: Dermatology Authors: Jeon YJ, Koo DW, Lee JS Tags: Br J Dermatol Source Type: research

Do we need to fear methotrexate?
PMID: 32147812 [PubMed - as supplied by publisher] (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - March 9, 2020 Category: Dermatology Authors: Haugaard JH, Egeberg A Tags: Br J Dermatol Source Type: research

Near total body vitiligo secondary to immunotherapy for metastatic melanoma.
PMID: 32147813 [PubMed - as supplied by publisher] (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - March 9, 2020 Category: Dermatology Authors: Olamiju B, Leventhal JS Tags: Br J Dermatol Source Type: research

Incidence, prevalence, and mortality of bullous pemphigoid in England 1998-2017: a population-based cohort study.
CONCLUSIONS: We report a modest increase in the incidence rate of bullous pemphigoid, but show that the burden of disease in the elderly population is considerable. Mortality is high, particularly in the first two years after diagnosis. PMID: 32147814 [PubMed - as supplied by publisher] (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - March 9, 2020 Category: Dermatology Authors: Persson MSM, Harman KE, Vinogradova Y, Langan SM, Hippisley-Cox J, Thomas KS, Gran S Tags: Br J Dermatol Source Type: research

"Mind the gap": What patients and clinicians believe is "unknown" about psoriasis.
"Mind the gap": What patients and clinicians believe is "unknown" about psoriasis. Br J Dermatol. 2020 Mar 09;: Authors: Majeed-Ariss R, McPhee M, McAteer H, Griffiths CEM, Young HS Abstract A Priority Setting Partnership (PSP) provides an opportunity for clinicians and patients to jointly decide the research priorities for a specific disease area. The James Lind Alliance (JLA), a non-profit making initiative established in 2004 which is funded by the National Institute for Health Research (NIHR), have developed methodology to facilitate PSPs. The JLA believe that medical research ...
Source: The British Journal of Dermatology - March 9, 2020 Category: Dermatology Authors: Majeed-Ariss R, McPhee M, McAteer H, Griffiths CEM, Young HS Tags: Br J Dermatol Source Type: research

Emergency management for preventing and controlling nosocomial infection of 2019 novel coronavirus: implications for the dermatology department.
Abstract As of Feb 15, 2019, the novel coronavirus (2019-nCoV) has rapidly spread throughout China and across the world with more than 60,000 laboratory-confirmed cases. Due to the current lack of specific treatment and the risk of transmission during the viral incubation period, infection prevention and control of 2019-nCoV are both urgent and critical to global health. In this article, we aim to highlight the necessity of implementing protective measures, and recommend how to set proper emergency management plans for preventing and controlling nosocomial infection of 2019-nCoV in dermatology departments. PM...
Source: The British Journal of Dermatology - March 5, 2020 Category: Dermatology Authors: Tao J, Song Z, Yang L, Huang C, Feng A, Man X Tags: Br J Dermatol Source Type: research

Evidence for interactions between filaggrin null mutations and environmental exposures in the aetiology of atopic dermatitis is currently lacking.
PMID: 32141071 [PubMed - as supplied by publisher] (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - March 5, 2020 Category: Dermatology Authors: Park YM, Seo SJ Tags: Br J Dermatol Source Type: research

Yes, accurately measuring and valuing health-related productivity loss is important, but can we afford any longer not to prevent and address it?
PMID: 32141072 [PubMed - as supplied by publisher] (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - March 5, 2020 Category: Dermatology Authors: Drabo EF, Levy JF, Gaskin DJ Tags: Br J Dermatol Source Type: research

The patient experience of pain in hidradenitis suppurativa.
Abstract Nielsen et al.1 recently highlighted the need for additional studies detailing hidradenitis suppurativa (HS) pain before giving specific treatment recommendations. Few studies have evaluated HS-specific pain using patients' own words and this study was designed to address this gap. A descriptive understanding of different elements of the pain experience will aid dermatologists, pain management specialists and health psychologists in the comprehensive, interdisciplinary assessment and treatment of HS. PMID: 32134499 [PubMed - as supplied by publisher] (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - March 5, 2020 Category: Dermatology Authors: Patel ZS, Hoffman LK, Sutton L, Cohen SR, Lowes MA, Seng EK Tags: Br J Dermatol Source Type: research

Ex vivo Confocal Microscopy: revolution in fast pathology in dermatology.
uig S Abstract Confocal Microscopy (CM) with in vivo and ex vivo modalities has been used in the evaluation of skin cancer and other dermatological disorders. Recent developments in ex-vivo CM allows for faster pathology assessment with greater accuracy by the visualisation of cellular and architectural details similar to standard pathology either in paraffin embedded or frozen samples. They include the possibility of multimodal confocal microscopy using different lasers and fusion images. New staining protocols including immunostaining with no damage to conventional histopathology preparation have been recently d...
Source: The British Journal of Dermatology - March 5, 2020 Category: Dermatology Authors: Malvehy J, Pérez-Anker J, Toll A, Pigem R, Garcia A, Alos LL, Puig S Tags: Br J Dermatol Source Type: research

Trends in malignant melanoma mortality in 31 countries from 1985 to 2015.
CONCLUSIONS: Overall increase in MM mortality over the past 30 years was observed. However, there was notable variation in mortality trends between countries, as well as between males and females, and between different age groups. PMID: 32133614 [PubMed - as supplied by publisher] (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - March 4, 2020 Category: Dermatology Authors: Yang DD, Salciccioli JD, Marshall DC, Sheri A, Shalhoub J Tags: Br J Dermatol Source Type: research

Survival in 31 670 patients with thin melanomas - a Swedish population-based study.
CONCLUSION: Long-term MSS was confirmed excellent for patients with thin CMMs in Sweden. Although we could show a decreased MSS for patients with 0·7 mm and above, the long-term survival and in addition a very favourable CMSS for those patients, do not support more extended follow-up programs than current recommendations in Sweden. PMID: 32133615 [PubMed - as supplied by publisher] (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - March 4, 2020 Category: Dermatology Authors: Isaksson K, Mikiver R, Eriksson H, Lapins J, Nielsen K, Ingvar C, Lyth J Tags: Br J Dermatol Source Type: research

Switching from one infliximab biosimilar (CT-P13) to another infliximab biosimilar (SB2) in patients with chronic plaque psoriasis.
Abstract CT-P13 and SB2 are two distinct biosimilars of the reference originator anti-tumour necrosis factor alpha monoclonal antibody infliximab. Real-life evidence has shown that the switch from infliximab originator to CT-P13 did not impair overall clinical efficacy and safety in patients with Crohn's disease, ulcerative colitis, spondyloarthritis, rheumatoid arthritis, psoriatic arthritis and chronic plaque psoriasis. PMID: 32133618 [PubMed - as supplied by publisher] (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - March 4, 2020 Category: Dermatology Authors: Gisondi P, Virga C, Piaserico S, Meneguzzo A, Odorici G, Conti A, Girolomoni G Tags: Br J Dermatol Source Type: research

Low-dose naltrexone in Hailey-Hailey disease: the importance of dosing.
Abstract We read with great interest the study by Jasans-Barceló et al. where they report the response of low-dose naltrexone in 8 patients of HHD.1 One interesting observation we made in the article was the response of one patient to the standard higher dose (50 mg) of naltrexone. Two previous studies that used the 50 mg dose in HHD patients (3 patients total) had failed to show any positive response. PMID: 32133619 [PubMed - as supplied by publisher] (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - March 4, 2020 Category: Dermatology Authors: Acharya P, Mathur M Tags: Br J Dermatol Source Type: research

Statins may reduce disease recurrence in patients with ulcerated primary melanoma.
CONCLUSION: Statins commenced before melanoma diagnosis, may reduce the risk of melanoma recurrence, especially in males and those with ulcerated tumours. Clinical trial evaluation of the potential role of statins in improving the prognosis of high-risk melanoma is warranted. PMID: 32133622 [PubMed - as supplied by publisher] (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - March 4, 2020 Category: Dermatology Authors: von Schuckmann LA, Khosrotehrani K, Ghiasvand R, Hughes MCB, van der Pols JC, Malt M, Smithers BM, Green AC Tags: Br J Dermatol Source Type: research

The association between partner bereavement and melanoma: cohort studies in the U.K. and Denmark.
CONCLUSIONS: We found decreased risk of melanoma diagnosis, but increased mortality associated with partner bereavement. These findings may be partly explained by delayed detection resulting from the loss of a partner who could notice skin changes. Stress may play a role in melanoma progression. Our findings indicate the need for a low threshold for skin examination in individuals whose partners have died. PMID: 32128788 [PubMed - as supplied by publisher] (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - March 3, 2020 Category: Dermatology Authors: Wong AYS, Frøslev T, Dearing L, Forbes HJ, Mulick A, Mansfield KE, Silverwood RJ, Kjaersgaard A, Sørensen HT, Smeeth L, Lewin A, Schmidt SAJ, Langan SM Tags: Br J Dermatol Source Type: research

Drug Survival of Adalimumab, Ustekinumab, and Secukinumab in Patients with Psoriasis: a Prospective Cohort Study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
CONCLUSIONS: Secukinumab and ustekinumab have similar sustained drug survival, whilst adalimumab has a lower drug survival in patients with psoriasis. Psoriatic arthritis and previous biologic experience were predictors with differential effects between the biologic therapies. PMID: 32124442 [PubMed - as supplied by publisher] (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - March 2, 2020 Category: Dermatology Authors: Yiu ZZN, Mason KJ, Hampton PJ, Reynolds NJ, Smith CH, Lunt M, Griffiths CEM, Warren RB, BADBIR Study Group Tags: Br J Dermatol Source Type: research

The effectiveness of dupilumab in alopecia areata patients with atopic dermatitis: a case series of seven patients.
Abstract Alopecia areata (AA) is one of the most common autoimmune diseases; however, the pathogenesis of the condition has yet to be fully elucidated. A recent study reported a case of severe AA associated with atopic dermatitis (AD) which was successfully treated with dupilumab, a monoclonal antibody against the α subunit of IL-4/IL-13 receptor. PMID: 32118289 [PubMed - as supplied by publisher] (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - March 2, 2020 Category: Dermatology Authors: Harada K, Irisawa R, Ito T, Uchiyama M, Tsuboi R Tags: Br J Dermatol Source Type: research

Evidence for a "window of opportunity" in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicenter cohort study.
Evidence for a "window of opportunity" in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicenter cohort study. Br J Dermatol. 2020 Mar 02;: Authors: Marzano AV, Genovese G, Casazza G, Moltrasio C, Dapavo P, Micali G, Sirna R, Gisondi P, Patrizi A, Dini V, Bianchini D, Bianchi L, Fania L, Prignano F, Offidani A, Atzori L, Bettoli V, Cannavò SP, Venturini M, Bongiorno MR, Costanzo A, Fabbrocini G, Peris K Abstract BACKGROUND: The anti-tumour necrosis factor (TNF)-α adalimumab is the only licenced biologic for moderate-to-severe hidradenitis suppur...
Source: The British Journal of Dermatology - March 2, 2020 Category: Dermatology Authors: Marzano AV, Genovese G, Casazza G, Moltrasio C, Dapavo P, Micali G, Sirna R, Gisondi P, Patrizi A, Dini V, Bianchini D, Bianchi L, Fania L, Prignano F, Offidani A, Atzori L, Bettoli V, Cannavò SP, Venturini M, Bongiorno MR, Costanzo A, Fabbrocini G, Peri Tags: Br J Dermatol Source Type: research

Determining the minimal important change scores of the Vitiligo Impact Scale (VIS)-22 and Dermatology Life Quality Index (DLQI) scores in Indian patients with vitiligo using anchor- and distribution-based approaches.
Abstract Dermatology-specific quality-of-life instruments such Dermatology Life Quality Index (DLQI), as well as vitiligo-specific instruments are available to study the quality of life of patients with vitiligo. Vitiligo Impact Scale (VIS)-22 is a validated vitiligo-specific instrument, and clinical meaning has been assigned to its absolute scores.1,2 The minimal important change (MIC) is the smallest difference in a score that is considered significant by the patient and/or physician. We conducted this study to determine the MIC scores of VIS-22 as well as DLQI scores in vitiligo. PMID: 32119113 [PubMed - a...
Source: The British Journal of Dermatology - March 2, 2020 Category: Dermatology Authors: Gupta V, Taneja N, Sati HC, Sreenivas V, Ramam M Tags: Br J Dermatol Source Type: research

Feasibility of a trial to evaluate nicotinamide for chemoprevention of skin cancers in organ transplant recipients in the UK.
Abstract Keratinocyte cancers (KC) are the commonest malignancies in the UK population, with rates increasing annually. Nicotinamide (vitamin B3) has recently been reported to reduce the incidence of KC in high-risk patients. It is a precursor of nicotinamide adenine dinucleotide (NAD+) which replenishes cellular energy levels and enhances efficient repair of ultraviolet light (UV) induced DNA damage within keratinocytes. PMID: 32119116 [PubMed - as supplied by publisher] (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - March 2, 2020 Category: Dermatology Authors: Gollins C, Shah A, Sinha K, Khan S, Paul N, Meeajun B, Abbott RA, Blasdale C, Cooper H, Harwood CA, Ismail F, Lear JT, Mackintosh L, McCormack S, Perrett CM, Proby CM, Durack A, Patalay R, Matin RN Tags: Br J Dermatol Source Type: research

Creating new guidelines on how best to treat foot symptoms in people with EB.
Abstract Epidermolysis bullosa (EB) is a complex rare condition that affects the skin and many parts of the body. Those born with EB have skin so fragile they are called 'butterfly children', their skin is quite simply as fragile as the wing of a butterfly. In the UK it is estimated that there are more than 5,000 people living with EB and 500,000 worldwide. Little clinical guidance for care existed until DEBRA International started a programme to develop clinical practice guidelines (CPGs). There were no previous guidelines and few published studies on foot care in EB so treatment decisions were largely based on i...
Source: The British Journal of Dermatology - March 1, 2020 Category: Dermatology Authors: Khan MT, O'Sullivan M, Faitli B, Mellerio JE, Fawkes R, Wood M, Hubbard LD, Harris AG, Iacobaccio L, Vlahovic T, James L, Brains L, Fitzpatrick M, Mayre-Chilton K Tags: Br J Dermatol Source Type: research

The need for strategies to address obesity and psoriatic arthritis prevention in psoriasis.
PMID: 32107778 [PubMed - in process] (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - March 1, 2020 Category: Dermatology Authors: Ogdie A, Eder L Tags: Br J Dermatol Source Type: research

Editor's Choice: rare skin diseases themed issue.
PMID: 32107779 [PubMed - in process] (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - March 1, 2020 Category: Dermatology Authors: Ingram J Tags: Br J Dermatol Source Type: research

Pachyonychia congenita, a paradigm for rare skin disorders.
PMID: 32107781 [PubMed - in process] (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - March 1, 2020 Category: Dermatology Authors: Steele L, O'Toole EA Tags: Br J Dermatol Source Type: research

Efficiency in patch testing: the number needed to test to get one relevant result as a new approach in the evaluation of baseline series.
acute;lez I, Giménez Arnau A Abstract Patch testing is a common procedure, where the baseline series is frequently used as a first screening. The number and the specific allergens of these series varies from country to country and keep changing over the years. Although the European Society of Contact Dermatitis (ESCD) made recommendations about patch testing1 , the decisions about the European baseline series were traditionally delegated to the European Environmental Contact Dermatitis Research Group (EECDRG)2 . A different, more reactive, approach has been recently proposed by the ESCD task force3 , using ...
Source: The British Journal of Dermatology - February 28, 2020 Category: Dermatology Authors: Gavín J, Mercader P, Descalzo MA, Garcia-Doval I, Silvestre JF, Sánchez-Pérez J, Fernández-Redondo V, Armario-Hita JC, Ruiz-González I, Giménez Arnau A Tags: Br J Dermatol Source Type: research

Measurement properties of the PROMIS Itch Questionnaire - itch severity assessments in adults with atopic dermatitis.
Abstract BACKGROUND: Little is known about the validity of numeric and verbal rating scales (NRS and VRS) for itch and itch frequency for assessing itch severity in AD. We evaluated the Patient-Reported Outcomes Information System (PROMIS® ) Itch Questionnaire (PIQ) - itch severity assessment, including multiple NRS, VRS and frequency of itch assessments, in adults with AD and compared their performance. METHODS: Self-administered questionnaires and skin-examination were performed in 410 AD patients (age 18-90 years) in a dermatology practice setting. RESULTS: PIQ NRS, VRS and frequency of itch had g...
Source: The British Journal of Dermatology - February 27, 2020 Category: Dermatology Authors: Silverberg JI, Lai JS, Patel K, Singam V, Vakharia PP, Chopra R, Sacotte R, Kantor R, Hsu DY, Cella D Tags: Br J Dermatol Source Type: research

What are the barriers to physical activity in patients with chronic plaque psoriasis?
CONCLUSION: Psoriasis-specific factors - severity, skin sensitivity, clothing choice, participation in social / leisure activities and treatments - contribute to exercise avoidance and may augment the increased risk of CVD in patients with psoriasis. PMID: 32107775 [PubMed - as supplied by publisher] (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - February 27, 2020 Category: Dermatology Authors: Auker L, Cordingley L, Pye DR, Griffiths CEM, Young HS Tags: Br J Dermatol Source Type: research

Trends and current spectrum of contact allergy in Central Europe: Results of the Information Network of Departments of Dermatology (IVDK), 2007 - 2018.
CONCLUSIONS: Decreases in sensitisation prevalence likely reflect reduced exposure, with some lag, as for hydroxyisohexyl 3-cyclohexene carboxaldehyde. If no (sufficient) decrease can be observed despite interventions, such as for nickel and chromium, affected subgroups should be identified and their causative exposures explored. Finally, increases like observed with propolis certainly warrant targeted investigation of exposures driving sensitisation, and possibly intervention. PMID: 32107776 [PubMed - as supplied by publisher] (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - February 27, 2020 Category: Dermatology Authors: Uter W, Gefeller O, Mahler V, Geier J Tags: Br J Dermatol Source Type: research

Skin cancer burden in lung transplant recipients: we need to do better!
PMID: 32100285 [PubMed - as supplied by publisher] (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - February 25, 2020 Category: Dermatology Authors: Proby CM, Harwood CA Tags: Br J Dermatol Source Type: research

Self-management: PROMs can prompt support.
PMID: 32090316 [PubMed - as supplied by publisher] (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - February 23, 2020 Category: Dermatology Authors: Pattinson R, Bundy C Tags: Br J Dermatol Source Type: research

Mercury exposure and nonmelanoma skin cancer: what're the odds?
PMID: 32090319 [PubMed - as supplied by publisher] (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - February 23, 2020 Category: Dermatology Authors: Taylor N Tags: Br J Dermatol Source Type: research